联合吸入舒利迭和噻托溴铵治疗慢性阻塞性肺疾病725例临床研究

Clinical Study of 725 Cases on Combined Inhaled Seretide and Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease

目的研究联合吸入舒利迭和噻托溴铵治疗慢性阻塞性肺疾病(COPD)稳定期的疗效及安全性。方法选取COPD患者725例,随机分为观察组364例,对照组361例。对照组给予噻托溴铵18μg,每日睡前吸入1次,60d为1个疗程;观察组加用舒利迭50μg/500μg,早晚各吸入1次,疗程同对照组。两组治疗前后进行症状评分及肺功能检查。结果两组患者治疗后症状积分均有改善,观察组疗效更加显著,P<0.05。两组患者治疗后肺功能均有改善,观察组疗效更加显著,P<0.05。安全性指标治疗前后差异无统计学意义,P>0.05。结论联合吸入噻托溴铵+舒利迭能有效减轻COPD患者临床症状,改善肺功能,安全可靠,值得临床推广。

Objective To study the combined inhaled seretide and tiotropium bromide in the treatment of chronic obstructive pulmonary disease（COPD）during the stable period of efficacy and safety. Methods 725 patients with COPD, were randomly divided into the observation group 364 cases, 361 cases of the control group. The control group was given tiotropium bromide 18~tg, daily bedtime inhaled 1 times, 60 days for a course of treatment; added to the observation group in 50g/500g, sooner or later the inhalation of 1, course of treatment and control group. In two groups before and after treatment, symptom score and pulmonary function examination. Results The two groups of patients after treatment of symptom scores have improved, the curative effect of therapeutic group was more significant at P〈 0.05. Two groups of patients after treatment of pulmonary function were all improved, the curative effect of therapeutic group was more significant at P 〈 0.05. Safety indexes before and after treatment had no significant difference between P 〉 0.05. Conclusion The combined inhalation of tiotropium bromide ＋ Seretide can effectively reduce COPD patients with clinical symptoms, improve lung function, safe and reliable, worthy of clinical application.